JP Morgan Chase
PCVX icon

JP Morgan Chase’s Vaxcyte PCVX Stock Holding History

JP Morgan Chase’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$2.46M – 7633
2024
Q4 		$2.46M Sell
30,000
-13,000
-30% -$1.29M ﹤0.01% 3990
2024
Q3 		$4.91M Buy
+43,000
New +$3.88M ﹤0.01% 3233
2024
Q2 		– Sell
-2,800
Closed -$191K – 7654
2024
Q1 		$191K Buy
+2,800
New +$194K ﹤0.01% 5380

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's PCVX Position: Q1 2026 in Review

JP Morgan Chase reduced its Vaxcyte (PCVX) stake by 7.1% in Q1 2026, selling an estimated $4.19M and leaving 1,008,314 shares worth $55.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

JP Morgan Chase first reported a position in PCVX in Q3 2020 and has held it in 23 quarters since. The position peaked at $163M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • JP Morgan Chase held 1,008,314 shares of Vaxcyte worth $55.4M as of Q1 2026.
  • JP Morgan Chase sold 77,205 Vaxcyte shares in Q1 2026, an estimated $4.19M.
  • Vaxcyte made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1333 holding.
  • JP Morgan Chase first reported a position in Vaxcyte in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Vaxcyte position peaked at $163M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.